This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tezepelumab for severe, uncontrolled asthma

< Back

Tezepelumab for severe, uncontrolled asthma


Cardiovascular Disease and Vascular Surgery

November 2020

Tezepelumab, as an add-on to current therapy, is in clinical development for the treatment of children and adults over 12 years old, with severe, uncontrolled asthma. Asthma is a common lung condition that causes wheezing, coughing and breathlessness. Individuals with asthma can suffer an asthma attack, which in severe cases can be fatal. Patients with severe asthma have ongoing daily symptoms despite high-intensity asthma treatment. Therefore, there is need for personalised treatment strategies which include a need for biological therapies which can specifically target the cause of an individual’s asthma.
Tezepelumab is a monoclonal antibody (protein) that targets proteins early in the inflammatory cascade. By targeting proteins early in the inflammatory cascade, several downstream inflammatory proteins are suppressed, thereby decreasing inflammation. Tezepelumab given as an add-on-therapy to patients with severe uncontrolled asthma has been shown to be safe, well tolerated, and effective. Tezepelumab is administered subcutaneously. If licensed, tezepelumab as an add on therapy would offer an additional biological therapy to those over 12 years old, with severe asthma.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts